Whistleblower Sarah Behnke's lawsuit leads to a $290 million judgment against CVS Caremark for overcharging Medicare on ...

CVS has emerged as an outlier during the ongoing implosion observed in the healthcare insurance sector, as they drive ...

Chief Judge Mitchell Goldberg tripled to $285 million the damages he had ordered CVS Caremark to pay in June, citing the ...

CVS Health (CVS) stock in focus as its pharmacy benefit manager CVS Caremark faces $289.9M in damages and penalties for ...

CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Notably, the case came from a whistleblower lawsuit filed by Sarah Behnke, a former Medicare Part D actuary at Aetna, who ...

UBS upgraded CVS Health (NYSE:CVS) to Buy from Neutral and raised its price target to $79, saying recent cost controls and execution in the company’s healthcare benefits arm are beginning to show ...

CVS Health, which operates the largest U.S. pharmacy benefit manager, will not add Gilead Sciences’ new HIV prevention drug ...

Through the power of strategic, well-built partnerships, CVS Health helps employees earn degrees — and at no cost to them.

A federal judge has ordered CVS Health's PBM Caremark to pay nearly $290 million after a whistleblower accused the business of overcharging Medicare on prescription drugs more than a decade ago.

A Pennsylvania judge has ordered CVS to pay $289 million in damages as part of a long-running whistleblower case. | A ...